<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/"><channel><title>心血管高季刊</title><link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_source=Chrome&amp;utm_campaign=pubmed-2&amp;ff=20230812060654&amp;utm_medium=rss&amp;utm_content=1 vU ePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;v=2.17.9。邮政6 +86293ac<description>心血管高季刊：PubMed 的最新结果</description><atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_source=Chrome&amp;utm_campaign=pubmed-2&amp;ff=20230812060654&amp;utm_medium=rss&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;v=2.17.9.post6+86293ac" rel="self"></atom:link><docs> http://www.rssboard.org/rss-specification</docs><generator> PubMed RSS 源 (2.17.9.post6+86293ac)</generator><language> zh</language><lastbuilddate> 2023 年 8 月 12 日星期六 10:06:55 +0000</lastbuilddate><pubDate> Fri, 11 Aug 2023 06:00:00 -0400</pubDate><ttl> 120</ttl><item><title> CCND2 修饰的 mRNA 激活小鼠和猪心肌梗死心脏中心肌细胞的细胞周期</title><link/>https://pubmed.ncbi.nlm.nih.gov/37565345/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230812060654&amp;v=2.17.9.post6+86293ac<description>结论：心肌内注射 CCND2-心肌细胞 SMRT 可促进心肌细胞增殖，减少梗塞面积，并改善患有 MI 的小型和大型哺乳动物心脏的心脏功能。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Circ Res. 2023 年 8 月 11 日。doi：10.1161/CIRCRESAHA.123.322929。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景：在哺乳动物心脏损伤模型中进行的实验表明，CCND2（细胞周期蛋白 D2，在人类中）的心肌细胞特异性过度表达可改善心肌梗死 (MI) 的恢复。（SMRT）可以诱导心肌细胞中的 CCND2 表达，并复制在其他心肌细胞中观察到的益处。心肌细胞特异性 CCND2 过表达对心肌修复的研究。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：CCND2 心肌细胞特异性修饰 mRNA 翻译系统（心肌细胞 SMRT）由 2 个 modRNA 构建体组成：1 个编码 CCND2，包含 L7Ae 的结合位点，另一个编码 L7Ae，包含心肌细胞特异性 microRNA 的识别元件miR-1和miR-208。因此，L7Ae抑制非心肌细胞中的CCND2翻译，但其本身被心肌细胞中的内源性miR-1和-208抑制，从而促进心肌细胞特异性CCND2表达。并且在用在单独使用 L7Ae modRNA 或与递送载体​​一起治疗的动物中以及在假手术动物中，SMRT 编码荧光素酶或 GFP 的心肌细胞特异性表达。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：CCND2-心肌细胞 SMRT 转染 2 天后，CCND2 在培养的有丝分裂后心肌细胞中大量表达，并且这种增加伴随着细胞周期激活和增殖标记物（例如 Ki67 和 Aurora B 激酶）的上调。将 GFP-心肌细胞 SMRT 心肌内注射到梗塞小鼠心脏中，在心肌细胞中观察到 GFP 信号，但在其他细胞类型中未观察到。在两种 MI 模型中，心肌细胞增殖（分别在小鼠和猪中治疗后第 7 天和第 3 天）均减少与对照组相比，接受 CCND2 心肌细胞 SMRT 治疗的动物的左心室射血分数（小鼠第 7 和 28 天，猪第 10 和 28 天）显着更高，梗塞（两个物种第 28 天）显着减少。接受 MI 诱导的任何其他组。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：心肌内注射 CCND2-心肌细胞 SMRT 可促进心肌细胞增殖，减少梗塞面积，并改善患有 MI 的小型和大型哺乳动物心脏的心脏功能。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37565345/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230812060654&v=2.17.9.post6+86293ac">37565345</a> | DOI： <a href=https://doi.org/10.1161/CIRCRESAHA.123.322929>10.1161/CIRCRESAHA.123.322929</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37565345</guid><pubDate> Fri, 11 Aug 2023 06:00:00 -0400</pubDate><dc:creator>孙家成</dc:creator><dc:creator>鹿王</dc:creator><dc:creator>雷切尔·C·马修斯</dc:creator><dc:creator>——格雷戈里·P·沃尔科特</dc:creator><dc:creator>陆玉安</dc:creator><dc:creator>魏玉华</dc:creator><dc:creator>扬州</dc:creator><dc:creator>利奥尔·赞吉</dc:creator><dc:creator>张建一</dc:creator><dc:date>2023-08-11</dc:date><dc:source>流通研究</dc:source><dc:title>CCND2 修饰的 mRNA 激活小鼠和猪心肌梗死心脏中心肌细胞的细胞周期</dc:title><dc:identifier>下午：37565345</dc:identifier><dc:identifier> doi:10.1161/CIRCRESAHA.123.322929</dc:identifier></item><item><title>瓣膜性心脏病和心肌病：重新评估它们的相互作用</title><link/>https://pubmed.ncbi.nlm.nih.gov/37563454/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230812060654&amp;v=2.17.9.post6+86293ac<description>心肌病和瓣膜性心脏病通常被认为是不同的诊断类别，并有专门的治疗指南。通过二尖瓣反流的发生。此外，心肌病和瓣膜性心脏病可以有一个共同的... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Nat Rev Cardiol。2023 年 8 月 10 日。doi：10.1038/s41569-023-00911-0。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">心肌病和瓣膜性心脏病通常被认为是不同的诊断类别，并有专门的治疗指南。此外，心肌病和瓣膜性心脏病可以有共同的病因，因为几种遗传或获得性疾病可以影响心脏瓣膜和心肌。因此，更好的方法了解它们共同的病理生理机制以及其相关性的患病率和诱发因素，可能会导致对这些疾病的风险分层和管理采取不同的方法。瓣膜性心脏病和心肌病共存的不同情况，强调了需要改进这些疾病的分类和聚类，对临床管理，特别是个性化治疗方法产生潜在影响。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37563454/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230812060654&v=2.17.9.post6+86293ac">37563454</a> | DOI： <a href=https://doi.org/10.1038/s41569-023-00911-0>10.1038/s41569-023-00911-0</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37563454</guid><pubDate> Thu, 10 Aug 2023 06:00:00 -0400</pubDate><dc:creator>尼娜·阿杰蒙·马桑</dc:creator><dc:creator>弗朗西斯卡·格拉齐亚尼</dc:creator><dc:creator>玛丽亚·基亚拉·梅乌奇</dc:creator><dc:creator>胡海伟</dc:creator><dc:creator>罗莎·利洛</dc:creator><dc:creator>杰伦·J·巴克斯</dc:creator><dc:creator>弗朗西斯科·布尔佐塔</dc:creator><dc:creator>马西莫·马塞蒂</dc:creator><dc:creator>J·沃特·朱克玛</dc:creator><dc:creator>菲利波·克雷亚</dc:creator><dc:date>2023-08-10</dc:date><dc:source> 《自然》评论、心脏病学</dc:source><dc:title>瓣膜性心脏病和心肌病：重新评估它们的相互作用</dc:title><dc:identifier>下午：37563454</dc:identifier><dc:identifier> doi:10.1038/s41569-023-00911-0</dc:identifier></item><item><title>原始预防会改变心脏病学吗？</title><link/> https://pubmed.ncbi.nlm.nih.gov/37563238/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230812060654&amp;v=2.17.9.post6+86293ac<description>没有摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 年 8 月 11 日：ehad459。doi：10.1093/eurheartj/ehad459。印刷前在线。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37563238/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230812060654&v=2.17.9.post6+86293ac">37563238</a> | DOI： <a href=https://doi.org/10.1093/eurheartj/ehad459>10.1093/eurheartj/ehad459</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37563238</guid><pubDate> Thu, 10 Aug 2023 06:00:00 -0400</pubDate><dc:creator>尤金·布劳瓦尔德</dc:creator><dc:date>2023-08-10</dc:date><dc:source>欧洲心脏杂志</dc:source><dc:title>原始预防会改变心脏病学吗？</dc:title><dc:identifier>下午：37563238</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad459</dc:identifier></item><item><title>西藏神秘塔卡吉亚面临气候变化的适应性进化</title><link/>https://pubmed.ncbi.nlm.nih.gov/37562403/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230812060654&amp;v=2.17.9.post6+86293ac<description>在快速变化的气候下，最极端的环境最容易发生转变。这些生态系统拥有一些最特化的物种，这些物种可能会遭受最高的灭绝率。我们记录了有记录以来海拔最高的气温上升（2010-2021 年）海拔超过 4,000 m，引发了高度适应的残余苔藓 Takakia lepidozioides 的衰退。其重新测序的基因组包含 27,467 个蛋白质编码基因，包括独特的适应... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Cell</b> . 2023 年 8 月 3 日：S0092-8674(23)00736-5.doi: 10.1016/j.cell.2023.07.003. 印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">在快速变化的气候下，最极端的环境最容易发生转变。这些生态系统拥有一些最特化的物种，这些物种可能会遭受最高的灭绝率。我们记录了有记录以来海拔最高的气温上升（2010-2021 年）海拔超过 4,000 m，引发了残存且高度适应的苔藓 Takakia lepidozioides 的衰退。其从头测序的基因组包含 27,467 个蛋白质编码基因，包括对非生物胁迫的独特适应，并包含数量最多的正选择下快速进化的基因研究地点在过去 6500 万年的抬升导致了危及生命的 UV-B 辐射和急剧降低的温度，我们检测到了 Takakia 对这些环境变化的几种分子适应。令人惊讶的是，特定的形态特征很可能更早发生在温暖得多的环境中，其数量超过 165 mya。经过近 4 亿年的进化和恢复，该物种现在正面临灭绝。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37562403/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230812060654&v=2.17.9.post6+86293ac">37562403</a> | DOI： <a href=https://doi.org/10.1016/j.cell.2023.07.003>10.1016/j.cell.2023.07.003</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37562403</guid><pubDate> Thu, 10 Aug 2023 06:00:00 -0400</pubDate><dc:creator>胡若阳</dc:creator><dc:creator>李学东</dc:creator><dc:creator>胡勇</dc:creator><dc:creator>张润杰</dc:creator><dc:creator>强吕</dc:creator><dc:creator>张敏更多</dc:creator><dc:creator>盛贤勇</dc:creator><dc:creator>赵峰</dc:creator><dc:creator>陈志佳</dc:creator><dc:creator>丁雨涵</dc:creator><dc:creator>浣媛</dc:creator><dc:creator>吴晓峰</dc:creator><dc:creator>双星</dc:creator><dc:creator>严晓宇</dc:creator><dc:creator>方宝</dc:creator><dc:creator>平湾</dc:creator><dc:creator>肖立红</dc:creator><dc:creator>王晓芹</dc:creator><dc:creator>韦晓</dc:creator><dc:creator>伊娃·L·德克尔</dc:creator><dc:creator>尼科·范格塞尔</dc:creator><dc:creator>休斯·雷诺</dc:creator><dc:creator>格特鲁德·维德曼</dc:creator><dc:creator>内莉·霍斯特更多</dc:creator><dc:creator>Fabian B Haas更多</dc:creator><dc:creator>佩尔·基·威尔海姆森</dc:creator><dc:creator>克里斯蒂安·K·乌尔里希</dc:creator><dc:creator>伊娃·诺伊曼</dc:creator><dc:creator>仓位</dc:creator><dc:creator>梁承志</dc:creator><dc:creator>杜惠龙</dc:creator><dc:creator>宏伟路</dc:creator><dc:creator>高强</dc:creator><dc:creator>成竹宽</dc:creator><dc:creator>尤涵立</dc:creator><dc:creator>辛培勇</dc:creator><dc:creator>褚金芳</dc:creator><dc:creator>黄建勋</dc:creator><dc:creator>杨柳</dc:creator><dc:creator>董珊珊</dc:creator><dc:creator>张良生</dc:creator><dc:creator>陈飞</dc:creator><dc:creator>邓雷</dc:creator><dc:creator>福州段</dc:creator><dc:creator>赵文霁</dc:creator><dc:creator>李凯</dc:creator><dc:creator>李中峰</dc:creator><dc:creator>李星如</dc:creator><dc:creator>崔恒建</dc:creator><dc:creator>张永娥</dc:creator><dc:creator>马川</dc:creator><dc:creator>朱瑞良</dc:creator><dc:creator>于佳</dc:creator><dc:creator>王美芝</dc:creator><dc:creator>长谷部光泰</dc:creator><dc:creator>付金忠</dc:creator><dc:creator>伯纳德·戈菲内特</dc:creator><dc:creator>红马</dc:creator><dc:creator>斯特凡·伦辛</dc:creator><dc:creator>拉尔夫·雷斯基</dc:creator><dc:creator>何宜坤</dc:creator><dc:date>2023-08-10</dc:date><dc:source>细胞</dc:source><dc:title>西藏神秘塔卡吉亚面临气候变化的适应性进化</dc:title><dc:identifier>下午：37562403</dc:identifier><dc:identifier> doi:10.1016/j.cell.2023.07.003</dc:identifier></item><item><title>健康和神经系统疾病中头骨骨髓的独特分子特征</title><link/>https://pubmed.ncbi.nlm.nih.gov/37562402/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230812060654&amp;v=2.17.9.post6+86293ac<description>头骨中的骨髓对于塑造大脑和脑膜的免疫反应非常重要，但其在骨骼中的分子组成以及与人类疾病的相关性仍不清楚。在这里，我们表明，与其他骨骼相比，小鼠头骨具有最独特的转录组特征在健康和受伤状态下，其特征是晚期中性粒细胞表型。在人类中，蛋白质组分析表明，颅骨骨髓是最独特的，具有差异表达...... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Cell</b> . 2023 年 8 月 3 日：S0092-8674(23)00742-0.doi: 10.1016/j.cell.2023.07.009.打印前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">头骨中的骨髓对于塑造大脑和脑膜的免疫反应非常重要，但其在骨骼中的分子组成以及与人类疾病的相关性仍不清楚。在这里，我们表明，与其他骨骼相比，小鼠头骨具有最独特的转录组特征在健康和损伤状态下，以晚期中性粒细胞表型为特征。在人类中，蛋白质组分析表明，颅骨骨髓是最独特的，具有差异表达的中性粒细胞相关途径和独特的突触蛋白特征。以及人类的细胞细节颅骨-脑膜连接（SMC）与静脉相比。最后，利用易位蛋白正电子发射断层扫描（TSPO-PET）成像，我们发现颅骨骨髓反映了各种神经系统疾病患者的炎症性脑反应，具有疾病特异性的空间分布头骨独特的分子特征以及解剖和功能连接显示了其作为诊断、监测和治疗脑部疾病的潜力。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37562402/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230812060654&v=2.17.9.post6+86293ac">37562402</a> | DOI： <a href=https://doi.org/10.1016/j.cell.2023.07.009>10.1016/j.cell.2023.07.009</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37562402</guid><pubDate> Thu, 10 Aug 2023 06:00:00 -0400</pubDate><dc:creator>泽内普·伊尔金·科拉巴斯</dc:creator><dc:creator>路易斯·B·库默勒</dc:creator><dc:creator>罗伯特·佩内茨基</dc:creator><dc:creator>本杰明福斯特拉</dc:creator><dc:creator>塞林·乌鲁卡亚</dc:creator><dc:creator>玛亚尔·阿里</dc:creator><dc:creator>萨克斯·卡普尔</dc:creator><dc:creator>劳拉·巴托斯</dc:creator><dc:creator>马伦·巴特纳</dc:creator><dc:creator>奥祖姆·塞纳兹·卡利斯坎</dc:creator><dc:creator>周易荣</dc:creator><dc:creator>麦洪成</dc:creator><dc:creator>卢西亚诺·霍赫</dc:creator><dc:creator>丹尼斯·杰里迪</dc:creator><dc:creator>穆格莫尔拜</dc:creator><dc:creator>——伊戈尔·卡林</dc:creator><dc:creator>扬尼斯·K·德利安尼斯</dc:creator><dc:creator>莫里茨·内格维尔</dc:creator><dc:creator>——肯尼·罗伯茨</dc:creator><dc:creator>阿尔巴·西马特</dc:creator><dc:creator>奥尔加·卡洛菲里奥</dc:creator><dc:creator>米哈伊尔·托多罗夫</dc:creator><dc:creator>伊莎贝拉·霍瓦斯</dc:creator><dc:creator>福尔坎·奥兹图尔克</dc:creator><dc:creator>塞琳娜·胡梅尔</dc:creator><dc:creator>格洛丽亚·比切勒</dc:creator><dc:creator>阿乔姆·扎特平</dc:creator><dc:creator>马库斯·温特莱纳</dc:creator><dc:creator>约翰内斯·格诺里奇</dc:creator><dc:creator>杰·鲁兹拉尔</dc:creator><dc:creator>约书亚·施劳德</dc:creator><dc:creator>帕迪斯·科斯拉瓦尼</dc:creator><dc:creator>本杰明·品味</dc:creator><dc:creator>丽莎·里克特</dc:creator><dc:creator>劳拉·迪亚兹·马鲁甘</dc:creator><dc:creator>多丽丝·卡尔特内克</dc:creator><dc:creator>劳林·勒克斯</dc:creator><dc:creator>陈瑛</dc:creator><dc:creator>赵山</dc:creator><dc:creator>鲍里斯·斯蒂芬·劳赫曼</dc:creator><dc:creator>——迈克尔·斯特尔</dc:creator><dc:creator>伊内斯·昆泽</dc:creator><dc:creator>凯伦·斯坦尼克</dc:creator><dc:creator>瓦妮莎·WY·坎</dc:creator><dc:creator>西蒙·贝松·吉拉德</dc:creator><dc:creator>萨布丽娜·卡兹多布勒</dc:creator><dc:creator>卡拉帕莱斯</dc:creator><dc:creator>朱莉娅·夏德勒</dc:creator><dc:creator>约翰内斯·帕措尔德</dc:creator><dc:creator>萨宾·利布歇尔</dc:creator><dc:creator>安雅·E·豪瑟</dc:creator><dc:creator>厄兹贡·格克切</dc:creator><dc:creator>海科·利克特</dc:creator><dc:creator>汉诺·斯坦克</dc:creator><dc:creator>科琳·贝纳基斯</dc:creator><dc:creator>克里斯蒂安·布劳恩</dc:creator><dc:creator>西莉亚·P·马丁内斯·希门尼斯</dc:creator><dc:creator>凯瑟琳娜·布尔格</dc:creator><dc:creator>— 纳塔莉·L·阿尔伯特</dc:creator><dc:creator>君特·霍格林格</dc:creator><dc:creator>约翰内斯·莱文</dc:creator><dc:creator>克里斯蒂安·哈斯</dc:creator><dc:creator>安娜·科普恰克</dc:creator><dc:creator>马丁·迪奇甘斯</dc:creator><dc:creator>约阿希姆·哈夫拉</dc:creator><dc:creator>塔尼亚·昆普费尔</dc:creator><dc:creator>马丁·克申施泰纳</dc:creator><dc:creator>玛蒂娜·希弗勒</dc:creator><dc:creator>——米凯尔·西蒙斯</dc:creator><dc:creator>阿瑟·利兹</dc:creator><dc:creator>娜塔莉·克莱默</dc:creator><dc:creator>奥马尔·拜拉克塔尔</dc:creator><dc:creator>尼古拉·弗朗茨迈尔</dc:creator><dc:creator>尼古拉斯·普莱斯尼拉</dc:creator><dc:creator>苏赫达·埃雷纳</dc:creator><dc:creator>维克多·G·普埃尔斯</dc:creator><dc:creator>克莱尔·德尔布里奇</dc:creator><dc:creator>哈沙兰·辛格·巴蒂亚</dc:creator><dc:creator>法里达·赫拉尔</dc:creator><dc:creator>马库斯·埃尔斯纳</dc:creator><dc:creator>英戈·贝克曼</dc:creator><dc:creator>本杰明·翁德鲁施卡</dc:creator><dc:creator>马蒂亚斯·布伦德尔</dc:creator><dc:creator>费边·J·泰斯</dc:creator><dc:creator>阿里·埃特克</dc:creator><dc:date>2023-08-10</dc:date><dc:source>细胞</dc:source><dc:title>健康和神经系统疾病中头骨骨髓的独特分子特征</dc:title><dc:identifier>下午：37562402</dc:identifier><dc:identifier> doi:10.1016/j.cell.2023.07.009</dc:identifier></item><item><title>人源化小鼠肝脏揭示了肝脏基本代谢功能的内皮控制</title><link/>https://pubmed.ncbi.nlm.nih.gov/37562401/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230812060654&amp;v=2.17.9.post6+86293ac<description>肝细胞是人体的主要代谢中心，执行人类特有的功能，在人类疾病中发生改变，目前认为通过内分泌和细胞自主机制进行调节。在这里，我们表明人类肝细胞的关键代谢功能受到控制由微环境中的非实质细胞 (NPC) 产生。我们开发了具有由人类肝细胞和 NPC 组成的人类肝组织的小鼠，其中包括人类免疫细胞、内皮细胞和星状细胞。人源化... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Cell</b> . 2023 年 8 月 1 日：S0092-8674(23)00795-X. doi: 10.1016/j.cell.2023.07.017. 印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">肝细胞是人体的主要代谢中心，执行人类特有的功能，在人类疾病中发生改变，目前认为通过内分泌和细胞自主机制进行调节。在这里，我们表明人类肝细胞的关键代谢功能受到控制由微环境中的非实质细胞 (NPC) 产生。我们开发了具有由人类肝细胞和 NPC 组成的人类肝组织的小鼠，其中包括人类免疫细胞、内皮细胞和星状细胞。人源化肝脏再现了人类肝脏结构，执行重要的人类特异性代谢/稳态过程，并模拟人类病理学，包括纤维化和非酒精性脂肪肝病 (NAFLD)。利用物种错配和脂质组学，我们证明人类 NPC 以旁分泌方式控制人类肝细胞的代谢功能。从机制上讲，我们发现了一个物种-肝窦内皮细胞分泌的WNT2通过受体FZD5控制肝细胞中胆固醇的摄取和胆汁酸结合的特异性相互作用。这些结果揭示了肝脏代谢的基本微环境调节及其人类特异性。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37562401/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230812060654&v=2.17.9.post6+86293ac">37562401</a> | DOI： <a href=https://doi.org/10.1016/j.cell.2023.07.017>10.1016/j.cell.2023.07.017</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37562401</guid><pubDate> Thu, 10 Aug 2023 06:00:00 -0400</pubDate><dc:creator>埃琳娜·卡夫</dc:creator><dc:creator>马诺利斯·鲁利斯</dc:creator><dc:creator>赵军</dc:creator><dc:creator>曲日豪</dc:creator><dc:creator>埃森·塞菲克</dc:creator><dc:creator>哈里斯·米尔扎</dc:creator><dc:creator>周静</dc:creator><dc:creator>郑云江</dc:creator><dc:creator>乔治亚州查尔科夫塔基</dc:creator><dc:creator>瓦西利斯·瓦西里乌</dc:creator><dc:creator>——丹尼尔·F·瓦特纳</dc:creator><dc:creator>Wajahat Z Mehal更多</dc:creator><dc:creator>阿尔克赫普网</dc:creator><dc:creator>无 尤瓦尔·克鲁格</dc:creator><dc:creator>理查德·A·弗拉维尔</dc:creator><dc:date>2023-08-10</dc:date><dc:source>细胞</dc:source><dc:title>人源化小鼠肝脏揭示了肝脏基本代谢功能的内皮控制</dc:title><dc:identifier>下午：37562401</dc:identifier><dc:identifier> doi:10.1016/j.cell.2023.07.017</dc:identifier></item><item><title>心律失常二尖瓣脱垂和二尖瓣环分离：病理生理学、风险分层和管理</title><link/>https://pubmed.ncbi.nlm.nih.gov/37561995/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230812060654&amp;v=2.17.9.post6+86293ac<description>二尖瓣脱垂（MVP）是最常见的瓣膜疾病，但在许多方面仍然是一个难题，特别是心律失常形式（AMVP）的存在和频率及其与心源性猝死的联系以及解剖功能特征的重要性称为二尖瓣环分离 (MAD) 的疾病仍然存在广泛争议。最近的病例系列和队列研究打破了 MVP 通常是良性的概念，并强调... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 年 8 月 10 日：ehad491。doi：10.1093/eurheartj/ehad491。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">二尖瓣脱垂（MVP）是最常见的瓣膜疾病，但在许多方面仍然是一个难题，特别是心律失常形式（AMVP）的存在和频率及其与心源性猝死的联系以及解剖功能特征的重要性称为二尖瓣环分离 (MAD) 的疾病仍存在广泛争议。最近的病例系列和队列研究打破了 MVP 通常是良性的概念，并强调了与临床显着室性心律失常相关的各种表型，包括 AMVP。定义、评估、后续向上，AMVP 的管理代表了本综述的重点，并通过最近定义心律失常 MVP 表型的一致研究得到加强，该表型将影响一小部分处于集中高风险的 MVP 患者。在这种情况下，本综述特别重要强调了 AMVP 表型和 MAD 的特征、其临床、多模态成像和节律评估、管理，并成为最近专家共识声明和新研究方向提案的对象。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37561995/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230812060654&v=2.17.9.post6+86293ac">37561995</a> | DOI： <a href=https://doi.org/10.1093/eurheartj/ehad491>10.1093/eurheartj/ehad491</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37561995</guid><pubDate> Thu, 10 Aug 2023 06:00:00 -0400</pubDate><dc:creator>本杰明·埃萨亚</dc:creator><dc:creator>阿维·萨巴格</dc:creator><dc:creator>爱德华·艾尔姆</dc:creator><dc:creator>若昂·L·卡瓦尔坎特</dc:creator><dc:creator>赫克托一世·米凯莱娜</dc:creator><dc:creator>莫里斯·恩里克斯·萨拉诺</dc:creator><dc:date>2023-08-10</dc:date><dc:source>欧洲心脏杂志</dc:source><dc:title>心律失常二尖瓣脱垂和二尖瓣环分离：病理生理学、风险分层和管理</dc:title><dc:identifier>下午：37561995</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad491</dc:identifier></item><item><title>经导管主动脉瓣植入治疗重度主动脉瓣狭窄和心源性休克患者：向前迈出了重要一步</title><link/>https://pubmed.ncbi.nlm.nih.gov/37559255/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230812060654&amp;v=2.17.9.post6+86293ac<description>没有摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 年 8 月 10 日：ehad471。doi：10.1093/eurheartj/ehad471。印刷前在线。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37559255/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230812060654&v=2.17.9.post6+86293ac">37559255</a> | DOI： <a href=https://doi.org/10.1093/eurheartj/ehad471>10.1093/eurheartj/ehad471</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37559255</guid><pubDate> Thu, 10 Aug 2023 06:00:00 -0400</pubDate><dc:creator>伯纳德·D·普伦德加斯特</dc:creator><dc:creator>——蒂芙尼·帕特森</dc:creator><dc:creator>西蒙·雷德伍德</dc:creator><dc:date>2023-08-10</dc:date><dc:source>欧洲心脏杂志</dc:source><dc:title>经导管主动脉瓣植入治疗重度主动脉瓣狭窄和心源性休克患者：向前迈出了重要一步</dc:title><dc:identifier>下午：37559255</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad471</dc:identifier></item><item><title>答复：因 COVID-19 住院的非重症患者的抗凝治疗</title><link/>https://pubmed.ncbi.nlm.nih.gov/37558380/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230812060654&amp;v=2.17.9.post6+86293ac<description>没有摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol.2023 年 8 月 15 日；82(7):e59-e60.doi:10.1016/j.jacc.2023.04.059。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37558380/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230812060654&v=2.17.9.post6+86293ac">37558380</a> | DOI： <a href=https://doi.org/10.1016/j.jacc.2023.04.059>10.1016/j.jacc.2023.04.059</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37558380</guid><pubDate> Wed, 09 Aug 2023 06:00:00 -0400</pubDate><dc:creator>格雷格·W·斯通</dc:creator><dc:creator>迈克尔·E·法库</dc:creator><dc:creator>瓦伦丁·福斯特</dc:creator><dc:date>2023-08-09</dc:date><dc:source>美国心脏病学会杂志</dc:source><dc:title>答复：因 COVID-19 住院的非重症患者的抗凝治疗</dc:title><dc:identifier>下午：37558380</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.04.059</dc:identifier></item><item><title>考虑对非危重症 COVID-19 患者进行全剂量抗凝治疗之前面临的挑战</title><link/>https://pubmed.ncbi.nlm.nih.gov/37558379/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230812060654&amp;v=2.17.9.post6+86293ac<description>没有摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol.2023 年 8 月 15 日；82(7):e57.doi: 10.1016/j.jacc.2023.05.053。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37558379/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230812060654&v=2.17.9.post6+86293ac">37558379</a> | DOI： <a href=https://doi.org/10.1016/j.jacc.2023.05.053>10.1016/j.jacc.2023.05.053</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37558379</guid><pubDate> Wed, 09 Aug 2023 06:00:00 -0400</pubDate><dc:creator>穆罕默德·阿吉尔巴斯里</dc:creator><dc:date>2023-08-09</dc:date><dc:source>美国心脏病学会杂志</dc:source><dc:title>考虑对非危重症 COVID-19 患者进行全剂量抗凝治疗之前面临的挑战</dc:title><dc:identifier>下午：37558379</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.05.053</dc:identifier></item><item><title>住院 COVID-19 患者的结果：SARS-CoV-2 变异体和疫苗接种状态是结果的重要混杂因素</title><link/>https://pubmed.ncbi.nlm.nih.gov/37558378/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230812060654&amp;v=2.17.9.post6+86293ac<description>没有摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol.2023 年 8 月 15 日；82(7):e55.doi: 10.1016/j.jacc.2023.03.431。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37558378/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230812060654&v=2.17.9.post6+86293ac">37558378</a> | DOI： <a href=https://doi.org/10.1016/j.jacc.2023.03.431>10.1016/j.jacc.2023.03.431</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37558378</guid><pubDate> Wed, 09 Aug 2023 06:00:00 -0400</pubDate><dc:creator>奥里魔杖</dc:creator><dc:creator>凯伦·科恩-哈盖</dc:creator><dc:date>2023-08-09</dc:date><dc:source>美国心脏病学会杂志</dc:source><dc:title>住院 COVID-19 患者的结果：SARS-CoV-2 变异体和疫苗接种状态是结果的重要混杂因素</dc:title><dc:identifier>下午：37558378</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.03.431</dc:identifier></item><item><title>低剂量秋水仙碱用于冠状动脉疾病二级预防：JACC 本周评论主题</title><link/>https://pubmed.ncbi.nlm.nih.gov/37558377/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230812060654&amp;v=2.17.9.post6+86293ac<description>在接受他汀类药物治疗的患者中，通过高敏 C 反应蛋白 (hsCRP) 评估的炎症是比低密度脂蛋白胆固醇 (LDL-C) 更强大的心血管死亡和全因死亡率决定因素。风险显着降低血管事件发生率。对于已经接受指南指导的医疗护理（包括他汀类药物）的冠状动脉疾病患者，低剂量秋水仙碱（0.5 毫克/天口服）已被证明可以... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol.2023 年 8 月 15 日；82(7):648-660.doi:10.1016/j.jacc.2023.05.055。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">在接受他汀类药物治疗的患者中，通过高敏 C 反应蛋白 (hsCRP) 评估的炎症是比低密度脂蛋白胆固醇 (LDL-C) 更强大的心血管死亡和全因死亡率决定因素。对于已经接受指南指导的医疗护理（包括他汀类药物）的冠心病患者，低剂量秋水仙碱（0.5 mg/d 口服）已被证明可以安全地将主要不良心血管事件降低 31%稳定的动脉粥样硬化和近期心肌梗塞后的 23%。这些益处大于当代辅助降脂药二级预防试验中所见的益处。小剂量秋水仙碱禁用于患有严重肾或肝功能障碍的患者，应暂时停用与克拉霉素、酮康唑、环孢菌素等具有相同代谢途径的药物合用时应停药。降脂和抑制炎症并不冲突，而是具有协同作用。未来，积极降低LDL-C和抑制炎症治疗的联合使用可能会提高治疗效果。成为大多数动脉粥样硬化患者的护理标准。2023 年 6 月，美国食品和药物管理局批准使用低剂量秋水仙碱，以降低患有动脉粥样硬化疾病的成年患者发生心肌梗塞、中风、冠状动脉血运重建和心血管死亡的风险或具有多种心血管疾病危险因素。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37558377/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230812060654&v=2.17.9.post6+86293ac">37558377</a> | DOI： <a href=https://doi.org/10.1016/j.jacc.2023.05.055>10.1016/j.jacc.2023.05.055</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37558377</guid><pubDate> Wed, 09 Aug 2023 06:00:00 -0400</pubDate><dc:creator>凯尔·纳尔逊</dc:creator><dc:creator>瓦伦丁·福斯特</dc:creator><dc:creator>——保罗·M·里德克</dc:creator><dc:date>2023-08-09</dc:date><dc:source>美国心脏病学会杂志</dc:source><dc:title>低剂量秋水仙碱用于冠状动脉疾病二级预防：JACC 本周评论主题</dc:title><dc:identifier>下午：37558377</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.05.055</dc:identifier></item><item><title>法洛四联症婴儿的管理：质疑传统智慧</title><link/>https://pubmed.ncbi.nlm.nih.gov/37558376/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230812060654&amp;v=2.17.9.post6+86293ac<description>没有摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol.2023 年 8 月 15 日；82(7):628-630.doi:10.1016/j.jacc.2023.06.008。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37558376/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230812060654&v=2.17.9.post6+86293ac">37558376</a> | DOI： <a href=https://doi.org/10.1016/j.jacc.2023.06.008>10.1016/j.jacc.2023.06.008</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37558376</guid><pubDate> Wed, 09 Aug 2023 06:00:00 -0400</pubDate><dc:creator>巴里·爱</dc:creator><dc:date>2023-08-09</dc:date><dc:source>美国心脏病学会杂志</dc:source><dc:title>法洛四联症婴儿的管理：质疑传统智慧</dc:title><dc:identifier>下午：37558376</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.06.008</dc:identifier></item><item><title>法洛四联症新生儿肺动脉发育不全</title><link/>https://pubmed.ncbi.nlm.nih.gov/37558375/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230812060654&amp;v=2.17.9.post6+86293ac<description>结论：尽管有这样的看法，但 sTOF 新生儿中 hPA 的存在并不会增加最终修复后死亡或再次干预的总体风险。hPA 队列中 PA 的生长情况较好。这些发现表明，hPA 的存在不会对新生儿的结局产生不利影响。短时飞行。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol.2023 年 8 月 15 日；82(7):615-627.doi:10.1016/j.jacc.2023.05.051。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景：患有症状性法洛四联症 (sTOF) 并伴有肺动脉发育不全 (hPA) 的新生儿被认为是高风险。需要数据来了解 hPA 对结果的影响以及理想的治疗策略。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">目的：本研究的目的是量化 hPA 对 sTOF 新生儿结局的影响，并衡量该策略对该人群肺动脉 (PA) 生长的影响。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：先天性心脏病研究合作组织对 2005 年至 2017 年患有 sTOF 的新生儿进行了回顾。hPA 的标准包括单侧 PA z 评分 &lt;-2.0 和对侧 PA z 评分 &lt;0。主要结局是死亡率。次要结局包括再次干预和 PA 生长。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：我们纳入了 542 名患有 sTOF 的新生儿，其中 188 名 (35%) 患有 hPA，354 名 (65%) 患有正常 PA，中位随访时间为 4.1 年。左右 hPA z 评分中位数为 -2.19（第 25-75 名）百分位数：-2.55 至 -1.94）和 -2.23（第 25-75 个百分位数：-2.64 至 -1.91）。分期修复（与初次 TOF 修复相比）在 hPA 队列中不太常见（36% vs 44%；P = 0.07） ). 各组之间的生存率相似（未调整 P = 0.16；调整 P = 0.25）。再干预在 hPA 组中更为常见（HR：1.28；95% CI：1.01-1.63；P = 0.044）；最终修复（HR： 1.21；95% CI：0.93-1.58；P = 0.16）。hPA 队列中 1 年时的 PA 增长更大，尤其是右侧 PA（P &lt; 0.001）。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：尽管有这样的看法，但 sTOF 新生儿中 hPA 的存在并不会增加最终修复后死亡或再次干预的总体风险。hPA 队列中 PA 的生长情况较好。这些发现表明，hPA 的存在不会对新生儿的结局产生不利影响。短时飞行。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37558375/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230812060654&v=2.17.9.post6+86293ac">37558375</a> | DOI： <a href=https://doi.org/10.1016/j.jacc.2023.05.051>10.1016/j.jacc.2023.05.051</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37558375</guid><pubDate> Wed, 09 Aug 2023 06:00:00 -0400</pubDate><dc:creator>克里斯托弗·J·佩蒂特</dc:creator><dc:creator>——安德鲁·C·格拉茨</dc:creator><dc:creator>——安德鲁·B·戈德斯通</dc:creator><dc:creator>马克·A·法</dc:creator><dc:creator>詹妮弗·C·罗马诺</dc:creator><dc:creator>设拉子·马斯卡蒂亚</dc:creator><dc:creator>保罗·柴</dc:creator><dc:creator>杰弗里·D·赞皮</dc:creator><dc:creator>杰弗里·梅多斯</dc:creator><dc:creator>乔治·T·尼科尔森</dc:creator><dc:creator>沙巴娜·沙哈纳瓦兹</dc:creator><dc:creator>阿塔尔·M·库雷希</dc:creator><dc:creator>考特尼·E·麦克拉肯</dc:creator><dc:creator>克里斯托弗·E·马西奥</dc:creator><dc:creator>萨罗什·P·巴特利瓦拉</dc:creator><dc:creator>Ivor B Asztalos更多</dc:creator><dc:creator>史蒂文·希兰</dc:creator><dc:creator>贾斯汀·D·史密斯</dc:creator><dc:creator>乔尔·佩图斯</dc:creator><dc:creator>阿萨德·贝什什更多</dc:creator><dc:creator>——詹姆斯·E·B·劳尔斯顿</dc:creator><dc:creator>克里斯·M·霍克</dc:creator><dc:creator>Amy L Pajk更多</dc:creator><dc:creator>——布莱恩·H·戈德斯坦</dc:creator><dc:date>2023-08-09</dc:date><dc:source>美国心脏病学会杂志</dc:source><dc:title>法洛四联症新生儿肺动脉发育不全</dc:title><dc:identifier>下午：37558375</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.05.051</dc:identifier></item><item><title>超越运动场的视野：日常生活中共同决策的范例</title><link/>https://pubmed.ncbi.nlm.nih.gov/37558374/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230812060654&amp;v=2.17.9.post6+86293ac<description>没有摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol.2023 年 8 月 15 日；82(7):612-614.doi:10.1016/j.jacc.2023.06.020。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37558374/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230812060654&v=2.17.9.post6+86293ac">37558374</a> | DOI： <a href=https://doi.org/10.1016/j.jacc.2023.06.020>10.1016/j.jacc.2023.06.020</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37558374</guid><pubDate> Wed, 09 Aug 2023 06:00:00 -0400</pubDate><dc:creator> Shankar Baskar更多</dc:creator><dc:creator>——理查德·乔塞克</dc:creator><dc:creator>大卫·斯帕</dc:creator><dc:date>2023-08-09</dc:date><dc:source>美国心脏病学会杂志</dc:source><dc:title>超越运动场的视野：日常生活中共同决策的范例</dc:title><dc:identifier>下午：37558374</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.06.020</dc:identifier></item><item><title>遗传性心脏病患者在电子游戏过程中出现致命心律失常</title><link/>https://pubmed.ncbi.nlm.nih.gov/37558373/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230812060654&amp;v=2.17.9.post6+86293ac<description>结论：虽然电子游戏相关的危及生命的心律失常的轶事案例已有报道，但在迄今为止最大的单中心研究中，我们表明这些情况极为罕见。虽然电子游戏可能对健康造成不良后果，但电子游戏的威胁游戏引发的猝死不应被用来试图限制玩游戏的时间。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol.2023 年 8 月 15 日；82(7):603-611.doi:10.1016/j.jacc.2023.06.019。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景：最近有报道称，电子游戏会导致易感人群出现危及生命的心律失常，但遗传性心脏病 (GHD) 中心脏事件在电子游戏环境中的患病率尚未确定。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">目的：在这项研究中，我们试图确定 GHD 电子游戏环境中发生心脏事件的发生率。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：对 2000 年 7 月至 2022 年 11 月期间在 Mayo Clinic 遗传心律诊所接受评估和治疗的所有患者进行回顾性分析，以确定在发生心脏事件时有玩电子游戏史的患者。发生在诊断之前，突破性心脏事件（BCE）用于诊断之后发生的事件。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：在 3,370 名 GHD 患者中（首次评估的平均年龄为 27 ± 19 岁，55% 为女性），1,079 名患者 (32%) 在诊断前曾发生过心脏事件，其中 5 名患者 (0.5%) 患有与电子游戏相关的疾病事件（儿茶酚胺能多形性室性心动过速 3 例、长 QT 综合征 1 例、室性早搏触发心室颤动 1 例）。诊断治疗后，431 例患者（13%）在随访期间出现≥1 BCE，其中 1 例电子游戏-相关的 BCE (0.2%) 发生在儿茶酚胺敏感的右流出道室性心动过速患者中。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> CONCLUSIONS: Although anecdotal cases of electronic gaming-associated life-threatening arrhythmias have been reported, in this largest single-center study to date, we show that these are extremely rare occurrences. While electronic gaming can have adverse health consequences, the threat of electronic gaming-triggered sudden death should not be used to try to curb time spent gaming.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37558373/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230812060654&v=2.17.9.post6+86293ac">37558373</a> | DOI: <a href=https://doi.org/10.1016/j.jacc.2023.06.019>10.1016/j.jacc.2023.06.019</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37558373</guid><pubDate> Wed, 09 Aug 2023 06:00:00 -0400</pubDate><dc:creator> Raquel Neves</dc:creator><dc:creator> Sahej Bains</dc:creator><dc:creator> J Martijn Bos</dc:creator><dc:creator> Ciorsti J MacIntyre</dc:creator><dc:creator> John R Giudicessi</dc:creator><dc:creator> Michael J Ackerman</dc:creator><dc:date> 2023-08-09</dc:date><dc:source> Journal of the American College of Cardiology</dc:source><dc:title> Fatal Cardiac Arrhythmias During Electronic Gaming in Patients With Genetically Mediated Heart Diseases</dc:title><dc:identifier> pmid:37558373</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.06.019</dc:identifier></item><item><title> Subcutaneous ICD in Congenital Heart Disease: Will Skin Deep Cut It?</title><link/> https://pubmed.ncbi.nlm.nih.gov/37558372/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230812060654&amp;v=2.17.9.post6+86293ac<description> No abstract </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol. 2023 Aug 15;82(7):600-602. doi: 10.1016/j.jacc.2023.06.011.</p><p> <b>NO ABSTRACT</b></p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37558372/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230812060654&v=2.17.9.post6+86293ac">37558372</a> | DOI: <a href=https://doi.org/10.1016/j.jacc.2023.06.011>10.1016/j.jacc.2023.06.011</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37558372</guid><pubDate> Wed, 09 Aug 2023 06:00:00 -0400</pubDate><dc:creator> Louise Harris</dc:creator><dc:creator> Melanie R Burg</dc:creator><dc:creator> Douglas Y Mah</dc:creator><dc:date> 2023-08-09</dc:date><dc:source> Journal of the American College of Cardiology</dc:source><dc:title> Subcutaneous ICD in Congenital Heart Disease: Will Skin Deep Cut It?</dc:title><dc:identifier> pmid:37558372</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.06.011</dc:identifier></item><item><title> Subcutaneous Implantable Cardioverter-Defibrillators in Patients With Congenital Heart Disease</title><link/> https://pubmed.ncbi.nlm.nih.gov/37558371/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230812060654&amp;v=2.17.9.post6+86293ac<description> CONCLUSIONS: In this nationwide study, patients with CHD represented 2% of all S-ICD implantations. Our findings emphasize the effectiveness and safety of S-ICD in this particularly high-risk population. (S-ICD French Cohort Study [HONEST]; NCT05302115). </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol. 2023 Aug 15;82(7):590-599. doi: 10.1016/j.jacc.2023.05.057.</p><p> <b>ABSTRACT</b> </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> BACKGROUND: Very few data have been published on the use of subcutaneous implantable cardioverter-defibrillators (S-ICDs) in patients with congenital heart disease (CHD). </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> OBJECTIVES: The aim of this study was to analyze outcomes associated with S-ICDs in patients with CHD. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> METHODS: This nationwide French cohort including all patients with an S-ICD was initiated in 2020 by the French Institute of Health and Medical Research. Characteristics at implantation and outcomes were analyzed in patients with CHD. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> RESULTS: From October 12, 2012, to December 31, 2019, among 4,924 patients receiving an S-ICD implant in 150 centers, 101 (2.1%) had CHD. Tetralogy of Fallot, univentricular heart, and dextro-transposition of the great arteries represented almost one-half of the population. Patients with CHD were significantly younger (age 37.1 ± 15.4 years vs 50.1 ± 14.9 years; P &lt; 0.001), more frequently female (37.6% vs 23.0%; P &lt; 0.001), more likely to receive an S-ICD for secondary prevention (72.3% vs 35.9%; P &lt; 0.001), and less likely to have severe systolic dysfunction of the systemic ventricle (28.1% vs 53.1%; P &lt; 0.001). Over a mean follow-up period of 1.9 years, 16 (15.8%) patients with CHD received at least 1 appropriate shock, with all shocks successfully terminating the ventricular arrhythmia. The crude risk of appropriate S-ICD shock was twice as high in patients with CHD compared with non-CHD patients (annual incidences of 9.0% vs 4.4%; HR: 2.1; 95% CI: 1.3-3.4); however, this association was no longer significant after propensity matching (especially considering S-ICD indication, P = 0.12). The burden of all complications (HR: 1.2; 95% CI: 0.7-2.1; P = 0.4) and inappropriate shocks (HR: 0.9; 95% CI: 0.4-2.0; P = 0.9) was comparable in both groups. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> CONCLUSIONS: In this nationwide study, patients with CHD represented 2% of all S-ICD implantations. Our findings emphasize the effectiveness and safety of S-ICD in this particularly high-risk population. (S-ICD French Cohort Study [HONEST]; NCT05302115).</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37558371/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230812060654&v=2.17.9.post6+86293ac">37558371</a> | DOI: <a href=https://doi.org/10.1016/j.jacc.2023.05.057>10.1016/j.jacc.2023.05.057</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37558371</guid><pubDate> Wed, 09 Aug 2023 06:00:00 -0400</pubDate><dc:creator> Victor Waldmann</dc:creator><dc:creator> Christelle Marquié</dc:creator><dc:creator> Francis Bessière</dc:creator><dc:creator> David Perrot</dc:creator><dc:creator> Frédéric Anselme</dc:creator><dc:creator> Nicolas Badenco</dc:creator><dc:creator> Sergio Barra</dc:creator><dc:creator> Géraldine Bertaux</dc:creator><dc:creator> Hugues Blangy</dc:creator><dc:creator> Pierre Bordachar</dc:creator><dc:creator> Serge Boveda</dc:creator><dc:creator> Michel Chauvin</dc:creator><dc:creator> Nicolas Clémenty</dc:creator><dc:creator> Gaël Clerici</dc:creator><dc:creator> Nicolas Combes</dc:creator><dc:creator> Pascal Defaye</dc:creator><dc:creator> Jean-Claude Deharo</dc:creator><dc:creator> Philippe Durand</dc:creator><dc:creator> Guillaume Duthoit</dc:creator><dc:creator> Romain Eschalier</dc:creator><dc:creator> Laurent Fauchier</dc:creator><dc:creator> Rodrigue Garcia</dc:creator><dc:creator> Olivier Geoffroy</dc:creator><dc:creator> Edouard Gitenay</dc:creator><dc:creator> Jean-Baptiste Gourraud</dc:creator><dc:creator> Charles Guenancia</dc:creator><dc:creator> Laurence Iserin</dc:creator><dc:creator> Peggy Jacon</dc:creator><dc:creator> Laurence Jesel-Morel</dc:creator><dc:creator> Fawzi Kerkouri</dc:creator><dc:creator> Didier Klug</dc:creator><dc:creator> Linda Koutbi</dc:creator><dc:creator> Fabien Labombarda</dc:creator><dc:creator> Magalie Ladouceur</dc:creator><dc:creator> Gabriel Laurent</dc:creator><dc:creator> Christophe Leclercq</dc:creator><dc:creator> Baptiste Maille</dc:creator><dc:creator> Alice Maltret</dc:creator><dc:creator> Grégoire Massoulié</dc:creator><dc:creator> Pierre Mondoly</dc:creator><dc:creator> Sandro Ninni</dc:creator><dc:creator> Pierre Ollitrault</dc:creator><dc:creator> Jean-Luc Pasquié</dc:creator><dc:creator> Bertrand Pierre</dc:creator><dc:creator> Pénélope Pujadas</dc:creator><dc:creator> Laure Champ-Rigot</dc:creator><dc:creator> Frédéric Sacher</dc:creator><dc:creator> Nicolas Sadoul</dc:creator><dc:creator> Alexandre Schatz</dc:creator><dc:creator> Pierre Winum</dc:creator><dc:creator> Paul-Ursmar Milliez</dc:creator><dc:creator> Vincent Probst</dc:creator><dc:creator> Eloi Marijon</dc:creator><dc:date> 2023-08-09</dc:date><dc:source> Journal of the American College of Cardiology</dc:source><dc:title> Subcutaneous Implantable Cardioverter-Defibrillators in Patients With Congenital Heart Disease</dc:title><dc:identifier> pmid:37558371</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.05.057</dc:identifier></item><item><title> Septal Myectomy: An Evolving Therapy for Obstructive Hypertrophic Cardiomyopathy</title><link/> https://pubmed.ncbi.nlm.nih.gov/37558370/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230812060654&amp;v=2.17.9.post6+86293ac<description> No abstract </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol. 2023 Aug 15;82(7):587-589. doi: 10.1016/j.jacc.2023.05.054.</p><p> <b>NO ABSTRACT</b></p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37558370/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230812060654&v=2.17.9.post6+86293ac">37558370</a> | DOI: <a href=https://doi.org/10.1016/j.jacc.2023.05.054>10.1016/j.jacc.2023.05.054</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37558370</guid><pubDate> Wed, 09 Aug 2023 06:00:00 -0400</pubDate><dc:creator> Hartzell V Schaff</dc:creator><dc:creator> Hao Cui</dc:creator><dc:date> 2023-08-09</dc:date><dc:source> Journal of the American College of Cardiology</dc:source><dc:title> Septal Myectomy: An Evolving Therapy for Obstructive Hypertrophic Cardiomyopathy</dc:title><dc:identifier> pmid:37558370</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.05.054</dc:identifier></item><item><title> First-in-Human Transapical Beating-Heart Septal Myectomy in Patients With Hypertrophic Obstructive Cardiomyopathy</title><link/> https://pubmed.ncbi.nlm.nih.gov/37558369/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230812060654&amp;v=2.17.9.post6+86293ac<description> CONCLUSIONS: TA-BSM is a safe and efficient minimally invasive procedure for septal reduction of heterogeneous HOCM. Compared with conventional septal myectomy, TA-BSM provides real-time evaluation to guide resection while reducing surgical trauma. (Transapical Beating-Heart Septal Myectomy in Patients With Hypertrophic Obstructive Cardiomyopathy; NCT05332691). </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol. 2023 Aug 15;82(7):575-586. doi: 10.1016/j.jacc.2023.05.052.</p><p> <b>ABSTRACT</b> </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> BACKGROUND: To simplify surgical septal reduction therapy for hypertrophic obstructive cardiomyopathy (HOCM), we developed a novel transapical beating-heart septal myectomy (TA-BSM) procedure. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> OBJECTIVES: In this study, we sought to evaluate the clinical utility of TA-BSM in a first-in-human trial. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> METHODS: Patients with HOCM were enrolled if they presented with drug-refractory disabling symptoms. TA-BSM was performed via minithoracotomy with the use of our beating-heart myectomy device under echocardiographic guidance, without the use of cardiopulmonary bypass. Repeated resections were performed to tailor the extent of the septal myectomy for sufficient abolishment of left ventricular outflow tract (LVOT) obstruction and mitral regurgitation (MR). The primary outcome measure was procedural success, defined by resting/provoked LVOT gradient &lt;30/50 mm Hg and residual MR grade ≤1+ (of 4+) at 3-month follow-up. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> RESULTS: A total of 47 patients aged 12 to 77 years were enrolled. Of the 46 patients who were followed for 3 months, 42 achieved procedural success. The maximal LVOT gradient decreased from 86 mm Hg (IQR: 67-114 mm Hg) at baseline to 19 mm Hg (IQR: 14-28 mm Hg) at 3 months. MR grade was ≤1+ in 3 patients at baseline and in 45 patients at 3 months. One patient died on postoperative day 10 owing to device-unrelated reasons. Other major adverse events included 1 delayed ventricular septal perforation and 1 intraoperative left ventricular apical tear. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> CONCLUSIONS: TA-BSM is a safe and efficient minimally invasive procedure for septal reduction of heterogeneous HOCM. Compared with conventional septal myectomy, TA-BSM provides real-time evaluation to guide resection while reducing surgical trauma. (Transapical Beating-Heart Septal Myectomy in Patients With Hypertrophic Obstructive Cardiomyopathy; NCT05332691).</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37558369/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230812060654&v=2.17.9.post6+86293ac">37558369</a> | DOI: <a href=https://doi.org/10.1016/j.jacc.2023.05.052>10.1016/j.jacc.2023.05.052</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37558369</guid><pubDate> Wed, 09 Aug 2023 06:00:00 -0400</pubDate><dc:creator> Jing Fang</dc:creator><dc:creator> Yani Liu</dc:creator><dc:creator> Ying Zhu</dc:creator><dc:creator> Rui Li</dc:creator><dc:creator> Rui Wang</dc:creator><dc:creator> Dao Wen Wang</dc:creator><dc:creator> Yunhu Song</dc:creator><dc:creator> Chenhe Li</dc:creator><dc:creator> Yue Chen</dc:creator><dc:creator> Lin Cheng</dc:creator><dc:creator> Kangchao Zheng</dc:creator><dc:creator> Yun Zhao</dc:creator><dc:creator> Shiliang Li</dc:creator><dc:creator> Cai Cheng</dc:creator><dc:creator> Liming Xia</dc:creator><dc:creator> Xiaoping Chen</dc:creator><dc:creator> Song Wan</dc:creator><dc:creator> Xiang Wei</dc:creator><dc:date> 2023-08-09</dc:date><dc:source> Journal of the American College of Cardiology</dc:source><dc:title> First-in-Human Transapical Beating-Heart Septal Myectomy in Patients With Hypertrophic Obstructive Cardiomyopathy</dc:title><dc:identifier> pmid:37558369</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.05.052</dc:identifier></item><item><title> Molecular mechanism for Tn7-like transposon recruitment by a type IB CRISPR effector</title><link/> https://pubmed.ncbi.nlm.nih.gov/37557170/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230812060654&amp;v=2.17.9.post6+86293ac<description> Tn7-like transposons have co-opted CRISPR-Cas systems to facilitate the movement of their own DNA. These CRISPR-associated transposons (CASTs) are promising tools for programmable gene knockin. A key feature of CASTs is their ability to recruit Tn7-like transposons to nuclease-deficient CRISPR effectors. However, how Tn7-like transposons are recruited by diverse CRISPR effectors remains poorly understood. Here, we present the cryo-EM structure of a recruitment complex comprising the Cascade... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Cell</b> . 2023 Aug 1:S0092-8674(23)00743-2. doi: 10.1016/j.cell.2023.07.010. Online ahead of print.</p><p> <b>ABSTRACT</b> </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> Tn7-like transposons have co-opted CRISPR-Cas systems to facilitate the movement of their own DNA. These CRISPR-associated transposons (CASTs) are promising tools for programmable gene knockin. A key feature of CASTs is their ability to recruit Tn7-like transposons to nuclease-deficient CRISPR effectors. However, how Tn7-like transposons are recruited by diverse CRISPR effectors remains poorly understood. Here, we present the cryo-EM structure of a recruitment complex comprising the Cascade complex, TniQ, TnsC, and the target DNA in the type IB CAST from Peltigera membranacea cyanobiont 210A. Target DNA recognition by Cascade induces conformational changes in Cas6 and primes TniQ recruitment through its C-terminal domain. The N-terminal domain of TniQ is bound to the seam region of the TnsC spiral heptamer. Our findings provide insights into the diverse mechanisms for the recruitment of Tn7-like transposons to CRISPR effectors and will aid in the development of CASTs as gene knockin tools.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37557170/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230812060654&v=2.17.9.post6+86293ac">37557170</a> | DOI: <a href=https://doi.org/10.1016/j.cell.2023.07.010>10.1016/j.cell.2023.07.010</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37557170</guid><pubDate> Wed, 09 Aug 2023 06:00:00 -0400</pubDate><dc:creator> Shukun Wang</dc:creator><dc:creator> Clinton Gabel</dc:creator><dc:creator> Romana Siddique</dc:creator><dc:creator> Thomas Klose</dc:creator><dc:creator> Leifu Chang</dc:creator><dc:date> 2023-08-09</dc:date><dc:source> Cell</dc:source><dc:title> Molecular mechanism for Tn7-like transposon recruitment by a type IB CRISPR effector</dc:title><dc:identifier> pmid:37557170</dc:identifier><dc:identifier> doi:10.1016/j.cell.2023.07.010</dc:identifier></item></channel></rss>